Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1028

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 November 2022 Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
15 November 2022 Discontinued. Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
25 June 2020 Company have advised this technology in no longer in development.
25 June 2020 Suspended. Topic is suspended

For further information on our processes and methods, please see our CHTE processes and methods manual